TAGRISSO (osimertinib) for Metastatic Non-small Cell Lung Cancer - Cancer Therapy Advisor

TAGRISSO (osimertinib) for Metastatic Non-small Cell Lung Cancer

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for TAGRISSO (osimertinib), indicated for metastatic non-small cell lung cancer (NSCLC).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 11: Clinical Pharmacology
Slide 16: Warnings and Precautions
Slide 20: Clinical Safety and Efficacy
Slide 26: Drug Storage and Supply
Slide 28: References

Next hm-slideshow in Slides